ScripHong Kong-listed Everest Medicines Limited is mulling tweaking its business strategy of in-licensing Asia territory rights to foreign drug candidates, with a potential focus on renal diseases taking
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Bangladesh Acquisition Adds To B